This is a working overview of LC-MS/MS, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-09-07 and is reviewed periodically as new material appears.
Analytical methods for SR9009 typically rely on liquid chromatography coupled with tandem mass spectrometry. The technique can separate the parent compound from related substances and detect low concentrations in biological matrices. Urine and blood are common samples in anti-doping testing, while in vitro studies may use cell culture media. Rapid metabolism and low expected concentrations make method validation important for reliable identification. Exact metabolite patterns can vary by species and are not fully mapped.
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not an approved medicine and has no established human therapeutic use. The compound appears in scientific literature as a tool for probing circadian and metabolic regulation. Online sellers often label it as a research chemical, sometimes using the nickname Stenabolic. Its chemical identity is distinct from selective androgen receptor modulators, stimulants, and peroxisome proliferator-activated receptor delta agonists. Researchers use it mainly in cell and animal experiments.
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved for human use | Investigational status in most countries |
| Sports status | Prohibited by WADA | Classified as non-approved or metabolic modulator |
| Common analytical method | LC-MS/MS | Used for trace detection in biological samples |
| Typical test matrices | Urine and blood | Sample choice depends on testing program |
| Human trial data | None published | Effects and safety are not established |
SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
SR9009 is not approved as a medicine by major regulatory agencies. It is commonly sold as a research chemical, a category that may fall outside customary drug approval and quality rules. In sports, the World Anti-Doping Agency lists SR9009 as a prohibited substance. Athletes who use it can face sanctions if it is detected in a sample. Legal status varies by country, and importation may be restricted. Enforcement practices differ across borders.
Detection of SR9009 in biological samples usually employs liquid chromatography coupled with tandem mass spectrometry. This method can identify the parent compound and sometimes metabolites in urine or blood. Because exposure can be low and clearance may be rapid, sample timing and limits of detection matter. Laboratories validate assays for sensitivity and specificity. Results are interpreted alongside chain-of-custody and quality-control records. Urine is the common matrix for anti-doping analysis, while blood may be used in research settings.
(5) Cystathionine-β-synthase (an enzyme which requires pyridoxal phosphate, the active form of vitamin B6) combines homocysteine and serine to produce cystathionine. Instead of degrading cystathionine via cystathionine-β-lyase, as in the biosynthetic pathway, cystathionine is broken down to cysteine and α-ketobutyrate via (6) cystathionine-γ-lyase. (7) The enzyme α-ketoacid dehydrogenase converts α-ketobutyrate to propionyl-CoA, which is metabolized to succinyl-CoA in a three-step process (see propionyl-CoA for pathway).
In January 2022, the U.S. DEA proposed scheduling five additional psychedelic tryptamines, including DiPT, 4-HO-DiPT (4-OH-DiPT), 5-MeO-DET, 5-MeO-MiPT, and 5-MeO-AMT. However, they subsequently withdrew this proposal in July 2022. This followed pushback and opposition from the psychedelic community and medical industry. In December 2023, the U.S. DEA proposed scheduling the DOx psychedelics DOC and DOI. As of late 2025, despite opposition to this proposal as well, these drugs are poised to become controlled substances in the near future.
Only five stable nuclides contain both an odd number of protons and an odd number of neutrons. The first four "odd-odd" nuclides occur in low mass nuclides, for which changing a proton to a neutron or vice versa would lead to a very lopsided proton-neutron ratio (21H, 63Li, 105B, and 147N; spins 1, 1, 3, 1). The only other entirely "stable" odd-odd nuclide, 180m73Ta (spin 9), is thought to be the rarest of the 251 stable nuclides, and is the only primordial nuclear isomer, which has not yet been observed to decay despite experimental attempts. Many odd-odd radionuclides (such as the ground state of tantalum-180) with comparatively short half-lives are known. Usually, they beta-decay to their nearby even-even isobars that have paired protons and paired neutrons. Of the nine primordial odd-odd nuclides (five stable and four radioactive with long half-lives), only 147N is the most common isotope of a common element. This is the case because it is a part of the CNO cycle. The nuclides 63Li and 105B are minority isotopes of elements that are themselves rare compared to other light elements, whereas the other six isotopes make up only a tiny percentage of the natural abundance of their elements.
Sources: en.wikipedia.org
This can be done to slides processed by the chemical fixation or frozen section slides. To see the tissue under a microscope, the sections are stained with one or more pigments. The aim of staining is to reveal cellular components; counterstains are used to provide contrast. The most commonly used stain in histology is a combination of hematoxylin and eosin (often abbreviated H&E). Hematoxylin is used to stain nuclei blue, while eosin stains the cytoplasm and the extracellular connective tissue matrix of most cells pink. There are hundreds of various other techniques which have been used to selectively stain cells. Other compounds used to color tissue sections include safranin, Oil Red O, congo red, silver salts and artificial dyes. Histochemistry refers to the science of using chemical reactions between laboratory chemicals and components within tissue. A commonly performed histochemical technique is the Perls' Prussian blue reaction, used to demonstrate iron deposits in diseases like Hemochromatosis. Recently, antibodies have been used to stain particular proteins, lipids and carbohydrates. Called immunohistochemistry, this technique has greatly increased the ability to specifically identify categories of cells under a microscope. Other advanced techniques include in situ hybridization to identify specific DNA or RNA molecules. These antibody staining methods often require the use of frozen section histology. These procedures above are also carried out in the laboratory under scrutiny and precision by a trained specialist medical laboratory scientist (a histoscientist).
== Post-match == Although Juventus won the 1996 Champions League final, the victory remains controversial because of accusations of doping. The Juventus team has been accused of using erythropoietin (EPO) and the matter went to trial in 2004. In November 2004, club doctor Riccardo Agricola was given a 22-month prison sentence and fined €2,000 for sporting fraud by providing performance-enhancing drugs, specifically EPO, to players between 1994 and 1998, Leading hematologist Giuseppe d'Onofrio said that it was "practically certain" that midfielders Antonio Conte and Alessio Tacchinardi had taken EPO to overcome brief bouts of anemia, and that it was "very probable" that seven other players – Alessandro Birindelli, Alessandro Del Piero, Didier Deschamps, Dimas, Paolo Montero, Gianluca Pessotto and Moreno Torricelli – had taken EPO in small doses. In April 2005, the Court of Arbitration for Sport gave the following advisory opinion, in part: "The use of pharmaceutical substances which are not expressly prohibited by sports law, and which cannot be considered as substances similar or related to those expressly prohibited, is not to be sanctioned by disciplinary measures. However, regardless of the existence or not of any judgement rendered by a State court, sports authorities are under the obligation to prosecute the use of pharmaceutical substances which are prohibited by sports law or any other anti-doping rule violation in order to adopt disciplinary measures." In December 2005, Agricola was acquitted of the charges by Turin's court of appeal.
=== National Organizing Committee/League of Revolutionaries for a New America (1993) === In the January 1993 issue of Rally, Comrades! "An Open Letter” calling for a new organization was signed by Marian Kramer, President of the National Welfare Rights Union and General Baker, a UAW member and founder of the League of Revolutionary Black Workers. In the same issue of the paper a "Call to form Organizing Committees to establish an organization to educate, organize, and finally lead the masses in the inevitable transformation of our society” was published. It was signed by five activists: Abdul Alkalimat, Nacho Gonzalez, Ethel Long-Scott, John Slaughter and Leona Smith. Also in that issue was a statement by the CLP supporting the Call. The new organization was initially called the National Organizing Committee and later became the League of Revolutionaries for a New America.
Sources: en.wikipedia.org
=== Biotic Theory === Most contemporary research into the origin of homochirality focuses on identifying abiotic mechanisms for chiral symmetry-breaking, amplification, and propagation/transmission that could have occurred during prebiotic synthesis of biomolecule precursors or during primitive replication/polymerization. Some early theories of biological homochirality in the 1950s suggested that homochiral biopolymers of both enantiomeric forms (e.g., both D-RNA and L-RNA) could have been present in the prebiotic Earth, and that polymers of the canonical enantiomeric forms were selected for due to improved chemical function. As an extension of this idea, it was also proposed that lifeforms containing both enantiomeric forms of molecular machinery could have arisen independently, and that evolution by natural selection eventually led to the complete dominance of one enantiomeric lifeform. This purely biotic theory is difficult to assess experimentally, and is not widely accepted or discussed in the scientific community.
== In popular culture == The 1993 film Jurassic Park, which is based on the 1990 novel Jurassic Park by Michael Crichton, features dinosaurs that were genetically altered so that they could not produce lysine, an example of engineered auxotrophy. This was known as the "lysine contingency" and was supposed to prevent the cloned dinosaurs from surviving outside the park, forcing them to depend on lysine supplements provided by the park's veterinary staff. In reality, no animal can produce lysine; it is an essential amino acid. In 1996, lysine became the focus of a price-fixing case, the largest in United States history. The Archer Daniels Midland Company paid a fine of US$100 million, and three of its executives were convicted and served prison time. Also found guilty in the price-fixing case were two Japanese firms (Ajinomoto, Kyowa Hakko) and a South Korean firm (Sewon). Secret video recordings of the conspirators fixing lysine's price can be found online or by requesting the video from the U.S. Department of Justice, Antitrust Division. This case gave the basis for the book The Informant: A True Story, and the movie The Informant!.
=== Pharmacokinetics === Venlafaxine is well absorbed, with at least 92% of an oral dose being absorbed into systemic circulation. It is extensively metabolized in the liver via the CYP2D6 isoenzyme to desvenlafaxine (O-desmethylvenlafaxine, now marketed as a separate medication named Pristiq), which is just as potent an SNRI as the parent compound, meaning that the differences in metabolism between extensive and poor metabolisers are not clinically important in terms of efficacy. Side effects, however, are reported to be more severe in CYP2D6 poor metabolisers. Steady-state concentrations of venlafaxine and its metabolite are attained in the blood within 3 days. Therapeutic effects are usually achieved within 3 to 4 weeks. No accumulation of venlafaxine has been observed during chronic administration in healthy subjects. The primary route of excretion of venlafaxine and its metabolites is via the kidneys. The half-life of venlafaxine is relatively short, so patients are directed to adhere to a strict medication routine, avoiding missing a dose. Even a single missed dose can result in withdrawal symptoms. Venlafaxine is a substrate of P-glycoprotein (P-gp), which pumps it out of the brain. The gene encoding P-gp, ABCB1, has the SNP rs2032583, with alleles C and T. The majority of people (about 70% of Europeans and 90% of East Asians) have the TT variant.
Sources: en.wikipedia.org
No. It is an investigational compound without approved therapeutic indications. It is sold for research purposes only in many jurisdictions.
Sports authorities prohibit it because it is not approved for human use and has potential performance-enhancing effects. It appears on anti-doping lists under non-approved or metabolic modulator categories.
Detection usually uses liquid chromatography-tandem mass spectrometry. The method targets the parent compound or its metabolites in urine or blood.
SR9009 is a synthetic REV-ERB agonist used in laboratory research. It is not an approved drug, and its effects in humans are not well characterized. It is often sold as a research chemical under the name Stenabolic.